Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Cytokinetics (CYTK) over the last 8 years, with Q2 2018 value amounting to $8.1 million.

  • Cytokinetics' Current Deferred Revenue rose 239.23% to $8.1 million in Q2 2018 from the same period last year, while for Jun 2018 it was $8.1 million, marking a year-over-year increase of 239.23%. This contributed to the annual value of $9.6 million for FY2017, which is 1875.93% up from last year.
  • Cytokinetics' Current Deferred Revenue amounted to $8.1 million in Q2 2018, which was up 239.23% from $15.8 million recorded in Q1 2018.
  • Cytokinetics' Current Deferred Revenue's 5-year high stood at $21.4 million during Q3 2015, with a 5-year trough of $900000.0 in Q4 2014.
  • Moreover, its 5-year median value for Current Deferred Revenue was $10.4 million (2014), whereas its average is $12.2 million.
  • In the last 5 years, Cytokinetics' Current Deferred Revenue crashed by 9387.8% in 2014 and then soared by 221755.56% in 2015.
  • Quarter analysis of 5 years shows Cytokinetics' Current Deferred Revenue stood at $900000.0 in 2014, then soared by 2217.56% to $20.9 million in 2015, then tumbled by 61.36% to $8.1 million in 2016, then rose by 18.76% to $9.6 million in 2017, then fell by 15.04% to $8.1 million in 2018.
  • Its Current Deferred Revenue stands at $8.1 million for Q2 2018, versus $15.8 million for Q1 2018 and $9.6 million for Q4 2017.